[Myocardial scintigraphy using cationic 99m Tc complexes].
This report summarizes the results which have been achieved by the use of 99mTc-labeled cationic complexes for myocardial scintigraphy. Radiopharmacological aspects of 99mTc(III)-Cl2 (DMPE)2 and 99mTc(I)-TBl as well as their scintigraphic behaviour in patients with coronary artery disease are described. In contrast to 99mTc-Cl2 (DMPE)2, 99mTc-TBl could be used successfully for the assessment of ischemic and infarcted myocardial tissue. Yet in general, 201Tl scintigraphic findings remained superior. However, from the considerable improvements achieved it is likely that soon a 99mTc-labeled tracer will be available to serve as clinical useful myocardial imaging agent.
D000818:Animals; D003327:Coronary Disease / Q000000981:diagnostic imaging; D004285:Dogs; D006321:Heart / Q000000981:diagnostic imaging*; D006801:Humans; D009570:Nitriles; D009942:Organometallic Compounds; D015609:Organotechnetium Compounds; D010720:Phosphines; D011877:Radionuclide Imaging
D009570:Nitriles; D009942:Organometallic Compounds; D015609:Organotechnetium Compounds; D010720:Phosphines; C043714:technetium Tc 99m hexakis(tert-butylisonitrile); C031898:technetium Tc 99m bis(1,2-dimethylphosphino)ethane
Myokardszintigraphie mit kationischen 99mTc-Komplexen.